At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
Apremilast +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Apremilast and Placebo for Dermatitis, Atopic Dermatitis. Completed, enrolled 191 participants across 31 sites in 3 countries.
Detailed Summary
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic Dermatitis
CountriesCanada, Japan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartJun 2014
Primary CompletionOct 2015
Study CompletionFeb 2016
TodayJul 2026
First PostedMar 14, 2014
Enrollment StartJun 1, 2014
Primary CompletionOct 1, 2015
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.3 years ago
Interventions
Apremilastdrug
Orally twice a day (BID)
Apremilastdrug
Orally twice a day (BID)
Placebodrug
Orally twice a day (BID)
Placebodrug
Orally twice a day (BID)